The pharmaceutical industry continues to be ahotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: peptide pharmacophores. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Innovation in pharma: peptide pharmacophores

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Peptide pharmacophores is a key innovation area in the pharmaceutical industry

Peptide pharmacophores, also known as peptide-based pharmacophores or peptidomimetics, are molecules or structures that mimic the binding properties and functions of peptides in drug design and development. They are designed to interact with specific biological targets, such as proteins or enzymes, similarly to natural peptides, but with enhanced properties like improved stability, bioavailability, or selectivity. Peptide pharmacophores have gained significance in drug discovery due to their potential therapeutic applications and versatility.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 80+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of peptide pharmacophores.

Key players in peptide pharmacophores – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to peptide pharmacophores

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Hangzhou DAC Biotech 148 Unlock Company Profile
Pfizer 77 Unlock Company Profile
F. Hoffmann-La Roche 31 Unlock Company Profile
Ipsen 31 Unlock Company Profile
Vascular BioSciences 28 Unlock Company Profile
Ellipses Pharma 20 Unlock Company Profile
Massachusetts General Hospital 19 Unlock Company Profile
Bristol-Myers Squibb 19 Unlock Company Profile
SignalChem Lifesciences 18 Unlock Company Profile
Canget BioTekpharma 18 Unlock Company Profile
W. L. Gore & Associates 16 Unlock Company Profile
Johnson & Johnson 15 Unlock Company Profile
Samjin Pharm 13 Unlock Company Profile
BerGenBio 12 Unlock Company Profile
Beijing Electronics 12 Unlock Company Profile
Curegenix 11 Unlock Company Profile
Council of Scientific and Industrial Research 10 Unlock Company Profile
Novartis 9 Unlock Company Profile
E. Merck 9 Unlock Company Profile
Purinomia Biotech 8 Unlock Company Profile
G1 Therapeutics 7 Unlock Company Profile
Verastem 7 Unlock Company Profile
Chang Gung Memorial Foundation 7 Unlock Company Profile
Mayo Clinic 7 Unlock Company Profile
Nekonal Sarl 6 Unlock Company Profile
Atara Biotherapeutics 6 Unlock Company Profile
Bayer Pharma (Bayer Schering Pharma) 6 Unlock Company Profile
WellMarker Bio 6 Unlock Company Profile
Bayer 6 Unlock Company Profile
Gilead Sciences 6 Unlock Company Profile
Regeneron Pharmaceuticals 6 Unlock Company Profile
Arterez 5 Unlock Company Profile
Enanta Pharmaceuticals 5 Unlock Company Profile
Incanthera 5 Unlock Company Profile
IncellDx 4 Unlock Company Profile
The Center for Molecular Medicine and Immunology 4 Unlock Company Profile
General Hospital 4 Unlock Company Profile
Cedars-Sinai Health System 4 Unlock Company Profile
AI Therapeutics 4 Unlock Company Profile
Oncozyme Pharma 4 Unlock Company Profile
The Corporation For Penn State 4 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 4 Unlock Company Profile
Signablok 4 Unlock Company Profile
20/20 GeneSystems 3 Unlock Company Profile
Helmholtz Association of German Research Centres 3 Unlock Company Profile
Lunella Biotech 3 Unlock Company Profile
Beijing Bio-Targeting Therapeutics Technology 3 Unlock Company Profile
Molecure 3 Unlock Company Profile
HUYA Bioscience International 3 Unlock Company Profile
Merrimack Pharmaceuticals 3 Unlock Company Profile

Source: GlobalData Patent Analytics

Hangzhou DAC Biotech is one of the leading patent filers in Peptide pharmacophores. Hangzhou DAC Biotech, a biopharmaceutical company, focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drugs. The company has multiple PCT international applications and more than 500 patent applications, of which 23 have been authorized in the US alone. Pfizer and Ipsen are some of the other key patent filers in peptide pharmacophores.

In terms of application diversity, Nekonal leads the pack, while E. Merck and Beijing Electronics stood in the second and third positions, respectively. By means of geographic reach, F. Hoffmann-La Roche held the top position, followed by Ellipses Pharma and SignalChem Lifesciences.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

This content was updated on 25 January 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.